Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.47 |
| ▸ | FNTB | P49356 | 4/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16079905 | 0.99 | FNTA (0.49) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL16079907 | 0.99 | FNTA (0.49) | FNTAFNTBPGGT1BALDH1A1ALOX15 | |
| SCHEMBL8459450 | 0.85 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL16079906 | 0.85 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL8459447 | 0.85 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL30757911 | 0.81 | ALOX15 (0.41) | FNTAFNTBPGGT1BALOX15 | |
| SCHEMBL14408750 | 0.81 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL5190960 | 0.81 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL16079895 | 0.80 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL16079891 | 0.80 | FNTA (0.51) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014151719-A1 | SUBLINGUAL FORMULATIONS INCLUDING GERANYLGERANYLACETONE AND GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140274967-A1 | Polyisoprenyl derivatives and uses thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274967-A1 | Polyisoprenyl derivatives and uses thereof | PHOSPHO1, GGPS1, PPIP5K2 | FNTA 5/4885FNTB 64/4885PGGT1B 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.